Semax and ADHD: Reading the Russian Evidence

Semax and attention-deficit/hyperactivity disorder (ADHD) deserve a more careful discussion than either “proven treatment” or “never studied.” Russian product labeling, a frequently cited hypothesis paper, animal experiments, and human brain-imaging research represent different kinds of evidence. This guide explains what each can establish—and where verification remains incomplete.

At a glance:

• A product label and a well-controlled clinical trial answer different questions.

• Attention behavior in mice and brain scans in healthy volunteers are not ADHD treatment outcomes.

• Country-specific use does not establish approval elsewhere or validate a research vial.

Publisher disclosure: Bio Research LLC operates Bio Peptides Labs. This commercially interested, AI-assisted summary is not an independent scientific review. It is an educational evidence appraisal, not an ADHD treatment guide; source-access limits appear below.

1. What does the Russian Semax label actually say?

Peptogen's published Russian instruction sheet for Semax 0.1% nasal drops includes use in children aged seven and older for “minimal brain dysfunctions,” including ADHD. The sheet carries registration number ЛС-002553. This is manufacturer-hosted product information, not an independently assessed clinical dataset. Russian Semax instruction sheet — PDF

That wording matters: saying ADHD has never appeared in Russian Semax labeling would be inaccurate. But the label alone cannot tell a reader how participants were allocated in a trial, how large a treatment effect was, or how completely harms were measured. It also does not establish an adult ADHD indication.

The current product-level Russian registry record was not successfully retrieved during this review. The statement above describes the document actually inspected, not a certification that it is the latest authorized version. Keep formulation, document date, country, and current registration status separate.

2. Which ADHD evidence can be verified?

The frequently cited 2007 paper is a hypothesis

Shih-Jen Tsai's paper in Medical Hypotheses proposes Semax as a possible ADHD and Rett-syndrome research candidate. It builds a rationale around dopamine and brain-derived neurotrophic factor, or BDNF. It does not report a trial enrolling people with ADHD or a measured ADHD treatment effect. Tsai, 2007 — original-paper abstract

A plausible mechanism is a reason to investigate. It is not evidence that a treatment improves symptoms, school or work functioning, or long-term outcomes. A title containing “ADHD” does not change the study design.

An older Russian report needs the original document

The manufacturer's pediatric page cites a 2000 Russian State Medical University report by Zavadenko and Petrukhin on Semax in childhood minimal brain dysfunction. The original report was not retrieved here. Its methods, outcome definitions, adverse-event tables, and completeness of reporting therefore remain unverified. Manufacturer's bibliography — provenance of the report citation

This is a reason to avoid two opposite mistakes: declaring that no Russian pediatric clinical work exists, or repeating internet response percentages as if the underlying report had been critically reviewed. Neither is justified by access to a citation alone.

3. What do the attention and brain-imaging studies show?

Kovalev and colleagues' 2021 Russian study examined CD-1 mice with different baseline exploratory-attention profiles. Semax increased an attention index in the lower-attention subgroup without changing the other reported exploratory-behavior measures. The investigators also studied receptor binding in the prefrontal cortex. These were animal behavioral and biochemical endpoints, not diagnosed human ADHD. Kovalev and colleagues, 2021 — original journal abstract

The authors discuss similarities with atomoxetine-related findings. That does not establish clinical equivalence to atomoxetine or justify replacing an ADHD medicine. Matching one experimental signal is not matching a treatment's overall benefits and risks.

Panikratova and colleagues' 2020 study examined resting-state brain connectivity in 52 healthy participants across Semax, Selank, and placebo conditions. It reported connectivity differences involving the amygdala and temporal cortex. It was not an ADHD patient trial or evidence that a Semax–Selank combination treats ADHD. Original publisher abstract

Brain imaging can help investigate biological activity. For an ADHD claim, the missing bridge is a demonstrated improvement in relevant patient outcomes—not simply a scan that changes.

4. How do Russia, Europe, and the United States differ?

Russia

The FDA's 2026 Semax briefing recognizes Russian registration of nasal-drop products. That is more specific than a general claim that a substance is “used overseas.” FDA briefing, printed page 21 — PDF

United Kingdom and European Union

UK government import guidance specifically describes MHRA's treatment of Semax as a medicine rather than a food and says marketing authorization is required for sale or supply. It is not an ADHD recommendation. UK government guidance, Semax section

NICE's ADHD medication recommendations name established alternatives, not Semax or Selank. This describes that guideline, not every clinician's practice or every country's law. NICE NG87, medication-choice recommendations

The EU has both centralized and national authorization routes. EMA explicitly explains that its website does not cover every nationally authorized medicine. This review did not verify an EU authorization for Semax, but it did not audit every national register; it cannot certify absence across all European countries. Russia and the UK are not EU member states. EMA's national-register explanation

United States

FDA's 2026 briefing states that Semax free base and acetate are not components of FDA-approved drugs. It says ADHD was not evaluated because supporting literature was not found; elsewhere it explains that some Russian-language clinical papers were excluded without verified English translations. Those scope limits make it inappropriate to turn the briefing into proof that no Russian work exists. The briefing is not a final agency determination. FDA briefing, printed pages 6–7 and 23

5. What can responsibly be concluded about safety and ADHD?

The Russian instruction sheet includes contraindications such as seizure history and anxiety-associated disorders, and mentions nasal irritation. It should not be summarized as an assurance of universal safety. Manufacturer-hosted instruction sheet

FDA's current compounding-risk page flags limited safety information and potential immune-response risks from aggregation or peptide-related impurities. Semax appears in the withdrawn-nomination section; withdrawal is not a safety clearance. FDA safety context

The evidence reviewed here does not establish Semax as an evidence-based replacement for standard ADHD care. It supports a narrower conclusion: there is a research rationale and Russian labeling history, but the directly appraisable ADHD clinical evidence is incomplete.

Before making a stronger conclusion, a reviewer would need the original pediatric report, clear diagnostic criteria, prespecified symptom and functional outcomes, credible blinding and comparators, full harms reporting, and independent replication. This review does not claim that every study worldwide has been located.

A named pharmaceutical formulation is also not interchangeable with a catalog powder, a modified peptide, or a mixture. Read the companion Selank anxiety and ADHD evidence review. For documentation questions, see our COA and analytical-method guide and research resource library.

Review method and source access

Sources checked September 27, 2026 included English and Russian searches using Semax/Семакс, ADHD/СДВГ, attention, and pediatric-report terminology. We inspected manufacturer-hosted labeling, original-study abstracts, selected FDA material, UK guidance, and EMA's registry explanation. ClinicalTrials.gov searches did not identify a qualifying Semax ADHD intervention record; a registry search cannot exclude unregistered or locally registered studies.

The original 2000 pediatric report and subscription-only imaging full text were not reviewed. Current Russian product-record verification and an exhaustive EU/EEA national-register review remain incomplete. Translations and interpretation were AI-assisted, not certified. This is a focused narrative review, not a systematic review, meta-analysis, or original research paper.

ADHD diagnosis and treatment decisions belong with a qualified clinician. Do not substitute research materials for prescribed care. Catalog materials are for lawful laboratory research only, not human or veterinary use; this guide supplies no dosing or administration instructions.